OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cance
2016/10/31
Signed Agreement with Cell Culture Company (C3) for Manufacturing ofClinical Grade Antibody to Support Planned Clinical Studies EDMONTON, ALBERTA, November 2, 2016 – OncoQuest Inc.(“OncoQuest’), a biopharmaceuticalcompany focused on the development and commercialization of immunotherapeuticproducts for the treatment of cancer, today announces that itsJoint Venture Partner in China, OncoVent Co., Ltd. (“OncoVent”) has launchedits clinical development program for Anti-MUC1 MAb AR20.5 for the treatment ofpancreatic cancer. Based on the previous clinical experience and recentlyannounced positi…
Details